Clinical Trials Logo
  1. Home
  2. Transitional Cell Carcinoma
  3. NCT02581982

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Transitional Cell Carcinoma Clinical Trial

Official title:
Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma

Clinical Trial Summary

This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving paclitaxel together with pembrolizumab may be an effective treatment for urothelial cancer.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To estimate the overall response rate (ORR) of pembrolizumab combined with paclitaxel. SECONDARY OBJECTIVES: I. To determine the safety and tolerability of pembrolizumab combined with paclitaxel. II. To calculate the progression-free survival (PFS) rate at 6 months. TERTIARY OBJECTIVES: I. To determine the immune effects of pembrolizumab combined with paclitaxel. II. To associate immune effects with tumor response. III. To explore changes in immune-regulatory micro ribonucleic acids (RNAs) as biomarkers of response. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up within 30 days and then every 3 months for 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02581982
Study type Interventional
Source Wake Forest University Health Sciences
Contact
Status Completed
Phase Phase 2
Start date April 6, 2016
Completion date December 19, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03296306 - Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Phase 3
Completed NCT00880334 - Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC Phase 2
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Withdrawn NCT04179110 - Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor Phase 2
Completed NCT00070070 - Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas Phase 1
Completed NCT00154687 - Weekly TP-HDFL in the Treatment of Advanced TCC Phase 2
Completed NCT03256877 - Detecting Transitional Cell Carcinoma From Haematuria
Withdrawn NCT04006691 - Efficacy and Safety of UGN-101 in Recurrent Patients Phase 3
Terminated NCT05052372 - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Completed NCT00714025 - A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy Phase 2
Terminated NCT01310803 - Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder Phase 3
Completed NCT00623831 - A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Phase 1
Completed NCT00173862 - Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Terminated NCT01438112 - Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Phase 2/Phase 3
Completed NCT00683059 - Single Agent Abraxane as Second Line Therapy in Bladder Cancer Phase 2
Recruiting NCT04811846 - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood N/A
Not yet recruiting NCT04878250 - Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder Phase 2
Completed NCT00633789 - Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Phase 2
Completed NCT00612326 - Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging N/A